newsfilter
← Latest News
GlobeNewswire·

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

Presented early data highlighting first successful objective clinical response using non-viral Sleeping Beauty TCR-T cell therapy in solid tumors at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference